請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78099
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 何佳安 | |
dc.contributor.author | Yin Lun Lau | en |
dc.contributor.author | 劉彥麟 | zh_TW |
dc.date.accessioned | 2021-07-11T14:42:12Z | - |
dc.date.available | 2021-11-02 | |
dc.date.copyright | 2016-11-02 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-18 | |
dc.identifier.citation | 1. Tang, Y.; Wang, Y.; Kiani, M. F.; Wang, B., Classification, treatment strategy, and associated drug resistance in breast cancer. Clin Breast Cancer 2016.
2. Yang, Y.-S.; Carney, R. P.; Stellacci, F.; Irvine, D. J., Enhancing radiotherapy by lipid nanocapsule-mediated delivery of amphiphilic gold nanoparticles to intracellular membranes. ACS Nano 2014, 8 (9), 8992-9002. 3. Shieh, Y.-A.; Yang, S.-J.; Wei, M.-F.; Shieh, M.-J., Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 2010, 4 (3), 1433-1442. 4. Barenholz, Y., Doxil(R)--the first FDA-approved nano-drug: lessons learned. Journal of Control Release 2012, 160 (2), 117-134. 5. Gabizon, A. A., Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Investigation 2001, 19 (4), 424-436. 6. Hsieh, T. C.; Wong, C.; John Bennett, D.; Wu, J. M., Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: an in silico and biochemical approach targeting integrin alphavbeta3. Internation Journal of Cancer 2011, 129 (11), 2732-2743. 7. Lin, H. Y.; Lansing, L.; Merillon, J. M.; Davis, F. B.; Tang, H. Y.; Shih, A.; Vitrac, X.; Krisa, S.; Keating, T.; Cao, H. J.; Bergh, J.; Quackenbush, S.; Davis, P. J., Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB Journal 2006, 20 (10), 1742-1744. 8. Leslie, E. M.; Deeley, R. G.; Cole, S. P., Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and Applied Pharmacology 2005, 204 (3), 216-237. 9. Bradley, G.; Ling, V., P-glycoprotein, multidrug resistance and tumor progression. Cancer and Metastasis Reviews 1994, 13 (2), 223-233. 10. Ho, J. A.; Fan, N. C.; Jou, A. F.; Wu, L. C.; Sun, T. P., Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC-LIF: liposomal carrier for enhanced drug delivery. Talanta 2012, 99, 683-688. 11. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S. W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K., Liposome: classification, preparation, and applications. Nanoscale Research Letters 2013, 8 (1), 102-102. 12. Kibria, G.; Hatakeyama, H.; Ohga, N.; Hida, K.; Harashima, H., Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. Journal of Control Release 2011, 153 (2), 141-148. 13. Szoka, F.; Papahadjopoulos, D., Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy of Sciences of the United States of America 1978, 75 (9), 4194-4198. 14. Cortesi, R.; Esposito, E.; Gambarin, S.; Telloli, P.; Menegatti, E.; Nastruzzi, C., Preparation of liposomes by reverse-phase evaporation using alternative organic solvents. Journal of Microencapsulation 1999, 16 (2), 251-256. 15. Pons, M.; Foradada, M.; Estelrich, J., Liposomes obtained by the ethanol injection method. International Journal of Pharmaceutics 1993, 95 (1), 51-56. 16. Deamer, D. W., Preparation and properties of ether-injection liposomes. Annals of the New York Academy of Sciences 1978, 308 (1), 250-258. 17. Liu, D.; Mori, A.; Huang, L., Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1992, 1104 (1), 95-101. 18. Woodbury, D. J.; Richardson, E. S.; Grigg, A. W.; Welling, R. D.; Knudson, B. H., Reducing liposome size with ultrasound: bimodal size distributions. Journal of Liposome Research 2006, 16 (1), 57-80. 19. Olson, F.; Hunt, C. A.; Szoka, F. C.; Vail, W. J.; Papahadjopoulos, D., Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1979, 557 (1), 9-23. 20. Berger, N.; Sachse, A.; Bender, J.; Schubert, R.; Brandl, M., Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. International Journal of Pharmaceutics 2001, 223 (1–2), 55-68. 21. Park, J. W.; Kirpotin, D. B.; Hong, K.; Shalaby, R.; Shao, Y.; Nielsen, U. B.; Marks, J. D.; Papahadjopoulos, D.; Benz, C. C., Tumor targeting using anti-her2 immunoliposomes. Journal of Controlled Release 2001, 74 (1–3), 95-113. 22. Lee, R. J.; Low, P. S., Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. Journal of Biological Chemistry 1994, 269 (5), 3198-3204. 23. Hynes, R. O., Integrins: Bidirectional, Allosteric Signaling Machines. Cell 2002, 110 (6), 673-687. 24. D'Souza, S. E.; Ginsberg, M. H.; Plow, E. F., Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends in Biochemical Sciences 1991, 16, 246-250. 25. Frisch, S. M.; Ruoslahti, E., Integrins and anoikis. Current Opinion in Cell Biology 1997, 9 (5), 701-706. 26. Ruegg, C.; Dormond, O.; Mariotti, A., Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta 2004, 1654 (1), 51-67. 27. Stupack, D. G.; Puente, X. S.; Boutsaboualoy, S.; Storgard, C. M.; Cheresh, D. A., Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. Journal of Cell Biology 2001, 155 (3), 459-470. 28. Cooper, C. R.; Chay, C. H.; Pienta, K. J., The Role of αvβ3 in prostate cancer progression. Neoplasia 2002, 4 (3), 191-194. 29. Sloan, E. K.; Pouliot, N.; Stanley, K. L.; Chia, J.; Moseley, J. M.; Hards, D. K.; Anderson, R. L., Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Research 2006, 8 (2), R20. 30. Liu, Z.; Wang, F.; Chen, X., Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Delivery Research 2008, 69 (6), 329-339. 31. Hood, J. D.; Cheresh, D. A., Role of integrins in cell invasion and migration. Nature Reviews Cancer 2002, 2 (2), 91-100. 32. Carreiras, F.; Denoux, Y.; Staedel, C.; Lehmann, M.; Sichel, F.; Gauduchon, P., Expression and localization of αv integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecologic Oncology 1996, 62 (2), 260-267. 33. Rolli, M.; Fransvea, E.; Pilch, J.; Saven, A.; Felding-Habermann, B., Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100 (16), 9482-9487. 34. Rocchi, P.; Beraldi, E.; Ettinger, S.; Fazli, L.; Vessella, R. L.; Nelson, C.; Gleave, M., Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Research 2005, 65 (23), 11083-93. 35. Bauerle, T.; Komljenovic, D.; Merz, M.; Berger, M. R.; Goodman, S. L.; Semmler, W., Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. International Journal of Cancer 2011, 128 (10), 2453-2462. 36. Takagi, J.; Petre, B. M.; Walz, T.; Springer, T. A., Global Conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002, 110 (5), 599-611. 37. Paradise, R. K.; Lauffenburger, D. A.; Van Vliet, K. J., Acidic extracellular pH promotes activation of integrin αvβ3. PLoS ONE 2011, 6 (1), e15746. 38. Lee, J.-O.; Rieu, P.; Arnaout, M. A.; Liddington, R., Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18). Cell 1995, 80 (4), 631-638. 39. Shimaoka, M.; Takagi, J.; Springer, T. A., Conformational regulation of integrin structure and function. Annual review of biophysics and biomolecular structure 2002, 31, 485-516. 40. Smith, J. W.; Piotrowicz, R. S.; Mathis, D., A mechanism for divalent cation regulation of beta 3-integrins. Journal of Biological Chemistry 1994, 269 (2), 960-967. 41. Frémont, L., Biological effects of resveratrol. Life Sciences 2000, 66 (8), 663-673. 42. Neve, R. M.; Chin, K.; Fridlyand, J.; Yeh, J.; Baehner, F. L.; Fevr, T.; Clark, L.; Bayani, N.; Coppe, J. P.; Tong, F.; Speed, T.; Spellman, P. T.; DeVries, S.; Lapuk, A.; Wang, N. J.; Kuo, W. L.; Stilwell, J. L.; Pinkel, D.; Albertson, D. G.; Waldman, F. M.; McCormick, F.; Dickson, R. B.; Johnson, M. D.; Lippman, M.; Ethier, S.; Gazdar, A.; Gray, J. W., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10 (6), 515-527. 43. Kopp, P., Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? European Journal of Endocrinology 1998, 138 (6), 619-620. 44. Siemann, E. H.; Creasy, L. L., Concentration of the phytoalexin resveratrol in wine. American Journal of Enology and Viticulture 1992, 43 (1), 49-52. 45. Rimm, E. B.; Giovannucci, E. L.; Willett, W. C.; Colditz, G. A.; Ascherio, A.; Rosner, B.; Stampfer, M. J., Prospective study of alcohol consumption and risk of coronary disease in men. The Lancet 1991, 338 (8765), 464-468. 46. Penumathsa, S. V.; Maulik, N., Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Canadian Journal of Physiology and Pharmacology 2009, 87 (4), 275-286. 47. Pozo-Guisado, E.; Lorenzo-Benayas, M. J.; Fernandez-Salguero, P. M., Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. International Journal of Cancer 2004, 109 (2), 167-173. 48. Pozo-Guisado, E.; Alvarez-Barrientos, A.; Mulero-Navarro, S.; Santiago-Josefat, B.; Fernandez-Salguero, P. M., The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochemical Pharmacology 2002, 64 (9), 1375-1386. 49. Pozo-Guisado, E.; Merino, J. M.; Mulero-Navarro, S.; Lorenzo-Benayas, M. J.; Centeno, F.; Alvarez-Barrientos, A.; Fernandez-Salguero, P. M., Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. International Journal of Cancer 2005, 115 (1), 74-84. 50. Diaz-Chavez, J.; Fonseca-Sanchez, M. A.; Arechaga-Ocampo, E.; Flores-Perez, A.; Palacios-Rodriguez, Y.; Dominguez-Gomez, G.; Marchat, L. A.; Fuentes-Mera, L.; Mendoza-Hernandez, G.; Gariglio, P.; Lopez-Camarillo, C., Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLoS One 2013, 8 (5), e64378. 51. Clément, M.-V.; Hirpara, J. L.; Chawdhury, S.-H.; Pervaiz, S., Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998, 92 (3), 996-1002. 52. Dörrie, J.; Gerauer, H.; Wachter, Y.; Zunino, S. J., Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Research 2001, 61 (12), 4731-4739. 53. Tinhofer, I.; Bernhard, D.; Senfter, M.; Anether, G.; Loeffler, M.; Kroemer, G.; Kofler, R.; Csordas, A.; Greil, R., Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. The FASEB Journal 2001, 15 (9), 1613-1615. 54. Bazzoni, G.; Ma, L.; Blue, M.-L.; Hemler, M. E., Divalent cations and ligands induce conformational changes that are highly divergent among β1 integrins. Journal of Biological Chemistry 1998, 273 (12), 6670-6678. 55. Shih, A.; Davis, F. B.; Lin, H.-Y.; Davis, P. J., Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. The Journal of Clinical Endocrinology & Metabolism 2002, 87 (3), 1223-1232. 56. Tien, C.-Y.; Jou, A. F.-j.; Fan, N.-C.; Chuang, M.-C.; Ho, J.-a. A., Preparation of liposomal progesterone and its application on the measurement of progesterone interpreted via electrochemical and colorimetrics sensing platforms. Electroanalysis 2013, 25 (4), 1017-1022. 57. Vellon, L.; Menendez, J. A.; Lupu, R., A bidirectional 'alpha(v)beta(3) integrin-ERK1/ERK2 MAPK' connection regulates the proliferation of breast cancer cells. Molecular Carcinogens 2006, 45 (10), 795-804. 58. Yeh, P. Y.; Chuang, S. E.; Yeh, K. H.; Song, Y. C.; Chang, L. L.; Cheng, A. L., Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 2004, 23 (20), 3580-3588. 59. Xu, Y.; Diao, Y.; Qi, S.; Pan, X.; Wang, Q.; Xin, Y.; Cao, X.; Ruan, J.; Zhao, Z.; Luo, L.; Liu, C.; Yin, Z., Phosphorylated Hsp27 activates ATM-dependent p53 signaling and mediates the resistance of MCF-7 cells to doxorubicin-induced apoptosis. Cell Signaling 2013, 25 (5), 1176-1185. 60. Yanagawa, M.; Ikemot, K.; Kawauchi, S.; Furuya, T.; Yamamoto, S.; Oka, M.; Oga, A.; Nagashima, Y.; Sasaki, K., Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BioMed Central Research Notes 2012, 5 (1), 1-8. 61. O'Brien, M. E. R., Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil') versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology 2004, 15 (3), 440-449. 62. Thorn, C. F.; Oshiro, C.; Marsh, S.; Hernandez-Boussard, T.; McLeod, H.; Klein, T. E.; Altman, R. B., Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011, 21 (7), 440-446. 63. E. M. Creagh; D. Sheehan; T. G. Cotter, Heat shock proteins – modulators of apoptosis in tumour cells. Leukemia 2000, 14 (7), 1161–1173. 64. Lindquist S., Craig E.A., The heat-shock proteins. Annual Review of Genetics 1988, 22, 631–677. 65. Koyasu S., Nishida E., Kadowaki T., Matsuzaki F., Iida K., Harada F., Kasuga M., Sakai H., Yahara I., Two mammalian heat shock proteins, HSP90 and HSP100, are actin-binding proteins. Proceedings of the National Academy of Sciences of the United States of America 1986, 83 (21), 8054–8058. 66. Wiech H., Buchner J., Zimmermann R., Jakob U., Hsp90 chaperones protein folding in vitro. Nature 1992, 358 (6382), 169–170. 67. Welch W. J., Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiological Reviews 1992, 72 (4), 1063–1081. 68. Beckmann R. P., Mizzen L. E., Welch W. J., Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly. Science 1990, 248 (4957), 850–854. 69. Mosser D. D., Caron A. W., Bourget L., Denis-Larose C., Massie B., Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Molecular Cell Biology 1997, 17 (9), 5317–5327. 70. Angelidis C. E., Lazaridis I., Pagoulatos G. N., Constitutive expression of heat-shock protein 70 in mammalian cells confers thermoresistance. European Journal of Biochemistry 1991, 199 (1), 35–39. 71. Samali A., Cotter T. G., Heat shock proteins increase resistance to apoptosis. Experimental Cell Research 1996, 223 (1), 163–170. 72. Frydman J., Hartl F. U., Molecular chaperone functions of hsp70 and hsp60 in protein folding. In: Morimoto R. I., Tissieres A., Georgopoulos C. (eds). Heat Shock Proteins and Molecular Chaperones Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York 1994, 251–283. 73. Samali A., Cai J., Zhivotovsky B., Jones D. P., Orrenius S., Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. The EMBO Journal 1999, 18 (8), 2040–2048. 74. Xanthoudakis S., Roy S., Rasper D., Hennessey T., Aubin Y., Cassady R., Tawa P., Ruel R., Rosen A., Nicholson D. W., Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis. The EMBO Journal 1999, 18 (8), 2049–2056. 75. Chretien P., Landry J., Enhanced constitutive expression of the 27- kDa heat shock proteins in heat-resistant variants from Chinese hamster cells. Journal of Cell Physiology 1988, 137 (1), 157–166. 76. Mehlen P., Preville X., Chareyron P., Briolay J., Klemenz R., Arrigo A. P., Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF-α and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. Journal of Immunology 1995, 154 (1), 363–374. 77. Benndorf R., Hayess K., Ryazantsev S., Wieske M., Behlke J., Lutsch G., Phosphorylation and supramolecular organization of murine small heat shock protein HSP25 abolish its actin polymerization inhibiting activity. Journal of Biological Chemistry 1994, 269 (32), 20780–20784. 78. Miron T., Vancompernolle K., Vandekerckhove J., Wilchek M., Geiger B., A 25-kD inhibitor of actin polymerization is a low molecular mass heat shock protein. Journal of Cell Biology 1991, 114 (2), 255–261. 79. Mehlen P., Schulze-Osthoff K., Arrigo A. P., Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death. Journal of Biological Chemistry 1996, 271 (28), 16510–16514. 80. Garrido C., Ottavi P., Fromentin A.., Hammann A, Arrigo A. P., Chauffert B., Mehlen P., HSP27 as a mediator of confluencedependent resistance to cell death induced by anticancer drugs. Cancer Research 1997, 57 (13), 2661–2667. 81. Jaattela M., Wissing D., Heat-shock proteins protect cells from monocyte cytotoxicity: possible mechanism of self-protection. The Journal of Experimental Medicine 1993, 177 (1), 231–236. 82. Enari M., Talanian R. V., Wong W. W., Nagata S., Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996, 380 (6576), 723–726. 83. Arrigo A. P., Small stress proteins: chaperones that act as regulators of intracellular redox state and programmed cell death. Biological Chemistry 1998, 379 (1), 19–26. 84. Kang S. H., Kang K. W., Kim K. H., Kwon B., Kim S. K., Lee H. Y., Kong S. Y., Lee E. S., Jang S. G., Yoo B. C., Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BioMed Central Cancer 2008, 8, 286-295. 85. Vargas-Roig L. M., Gago F. E., Tello O., Aznar J. C., Ciocca D. R., Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. International Journal of Cancer 1998, 79 (5), 468–475. 86. Ciocca D. R., Calderwood S. K., Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10 (2), 86-103. 87. Tweedle E. M., Khattak I., Ang C. W., Nedjadi T., Jenkins R., Park B. K., Kalirai H., Dodson A., Azadeh B., Terlizzo M., Grabsch H., Mueller W., Myint S., Clark P., Wong H., Greenhalf W., Neoptolemos J. P., Rooney P. S., Costello E., Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut 2010, 59 (11), 1501-1510. 88. Stuart K. Calderwood, Md Abdul Khaleque, Douglas B. Sawyer, Daniel R. Ciocca. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends in Biochemical Sciences 2006, 31 (3), 164–172. 89. Teimourian S., Jalal R., Sohrabpour M., Goliaei B., Down-regulation of Hsp27 radiosensitizes human prostate cancer cells. International Journal of Urology 2006 13 (9), 1221-1225. 90. Tsuruta M., Nishibori H., Hasegawa H., Ishii Y., Endo T., Kubota T., Kitajima M., Kitagawa Y., Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer. Oncology Reports 2008, 20 (5), 1165-1172. 91. Barbara Lelj-Garolla, Masafumi Kumano, Eliana Beraldi, Lucia Nappi, Palma Rocchi, Diana N. Ionescu, Ladan Fazli, Amina Zoubeidi, Martin E. Gleave, Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Molecular Cancer Therapeutics 2015, 14 (5), 1107-1116. 92. Kristina Bram Knudsen, Helle Northeved, Pramod Kumar E. K., Anders Permin, Torben Gjetting, Thomas L. Andresen, Steen Larsen, Karen Malene Wegener, Jens Lykkesfeldt, Kim Jantzen, Steffen Loft, Peter M?ller, Martin Roursgaard, In vivo toxicity of cationic micelles and liposomes. Nanomedicine: Nanotechnology, Biology, and Medicine 2015, 11 (2), 467–477. 93. Gilad Haran, Rivka Cohen, Liliana K. Bar, Yechezkel Barenholz, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et Biophysica Acta 1993, 1151 (2), 201-215. 94. Lawrence E. Hightower, Heat shock, stress proteins, chaperones, and proteotoxicity. Cell, 1991, 66 (2), 191–197. 95. Lindquist, S. and E.A. Craig, The heat shock proteins. Annual Review of Genetics, 1988, 22, 631–677. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78099 | - |
dc.description.abstract | 白藜蘆醇(Resveratrol)是一個擁有抗癌效果的天然物質,可以從多種植物取得。在過去研究中,將白藜蘆醇修飾在硬脂酸上可以與其他磷脂一起形成微脂體。因為白藜蘆醇能夠與腫瘤相關的組合蛋白αvβ3進行結合,因此我們預計白藜蘆醇修飾在硬脂酸上可以增加微脂體到達腫瘤區域的能力。在本研究中我們著重於開發出一個有優良抗癌功能的奈米藥物去抑制人類乳癌細胞株MCF-7的生長。我們嘗試利用修飾上白藜蘆醇的硬脂酸(Resveratrol-modified stearate,RMS)去合成微脂體(RMS-Lipo),並在微脂體內包覆阿黴素(Doxorubicin),製備出RMS-Lipo-Dox,藉此標靶含有組合蛋白αvβ3活化態的MCF-7細胞。於細胞毒殺實驗結果中顯示,當MCF-7細胞受到RMS比例越高的RMS-Lipo-Dox處理後,MCF-7細胞的存活率就越低;在組合蛋白αvβ3表現量低的乳癌細胞株MDA-MB-231,則沒有明顯的RMS效應。過去文獻發現,白藜蘆醇可以經由減少熱休克蛋白27(hsp27)的表現,並誘導ERK1/2和p53磷酸化去抑制癌細胞生長。所以,我們預測當RMS接上組合蛋白αvβ3,可以誘導下游路徑的產生,促進MCF-7細胞凋亡。在目前西方墨點法的結果中可以得知,修飾在硬脂酸上的白藜蘆醇可以誘導hsp27的表現量明顯下降,表示細胞失去它的保護作用,會更容易被阿黴素所毒殺。歸納以上的實驗結果,我們發現利用修飾白藜蘆醇的硬脂酸可以誘導其下游的訊息傳遞,有效地提高包覆阿徽素的微脂體的治療效果。由此我們認為RMS-Lipo-Dox有潛力被使用在各種大量表現組合蛋白αvβ3的癌症治療上。 | zh_TW |
dc.description.abstract | Resveratrol, a natural polyphenol compound, is extracted from various plants. It has been investigated long on its chemopreventive activity against human cancer. In the past, research found that resveratrol was able to modify on stearic acid to expand the usage of resveratrol, which can form liposome with other phospholipids. While resveratrol can bind to integrin αvβ3, which was tumor-associated, we hypothesized resveratrol on the surface can render liposome a targeting ability to tumor environment. In this study, we tried to develop a nanodrug with remarkable antiproliferative activity on MCF-7, human breast cancer cell line. Herein, we used resveratrol modified stearate (RMS) as one of the constituents to prepare doxorubicin-encapsulating liposomes (RMS-Lipo-Dox). This nanoformulation would specifically bind to activated integrin αvβ3, resulted in the enhanced cytotoxicity of Dox on MCF-7 through signaling pathways triggered by RMS. From cytotoxicity assays, MCF-7 treated with increasing percentage of RMS-Lipo-Dox exhibited decreasing cell viability, but not another breast cancer cell line, MDA-MB-231, expressing low level of integrin αvβ3. Furthermore, it was reported that resveratrol can reduce expression of Hsp27 in MCF-7 cells. Our immunoblotting results showed the expression of heat shock protein 27 (hsp27) decreased after treated with 7.5% RMS-Lipo. This implied that MCF-7 cells lost protection to environmental stress and became more vulnerable to Dox. Summarizing
these results above, we demonstrated that RMS-Lipo-Dox can induce MCF-7 cells apoptosis through downregulation of hsp27, which enhanced cytotoxicity of liposomal Dox. We proposed that RMS-Lipo-Dox is a potential therapeutic agent on integrin αvβ3-overexpressed cancers. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:42:12Z (GMT). No. of bitstreams: 1 ntu-105-R03b22029-1.pdf: 2768491 bytes, checksum: 9575fef6ac1aa361fe4b1eaf91174134 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 謝誌.................................................................................................................................i
Abstract..........................................................................................................................ii 中文摘要.......................................................................................................................iv Contents..........................................................................................................................v List of Figures and Tables.............................................................................................vii Chapter 1 Introduction 1-1 Drug Delivery System....................................................................................1 1-2 Liposomes......................................................................................................2 1-2.1 Manufacture of Liposomes.................................................................3 1-2.2 Modification of Liposomes.................................................................5 1-3 Integrins........................................................................................................7 1-3.1 Binding Ligands of Integrins..............................................................7 1-3.2 Integrin αvβ3........................................................................................8 1-3.3 Activation of Integrin αvβ3..................................................................9 1-3.4 Signal Transduction of Integrin αvβ3.................................................11 1-4 Resveratrol...................................................................................................13 1-4.1 Anti-cancer Ability of Resveratrol....................................................14 1-5 Heat Shock Proteins......................................................................................15 1-5.1 Inhibiting Apoptosis by Hsp27.........................................................17 1-5.2 Regulating Hsp27 Level to Benefit Cancer Treatment......................17 1-6 Motivation and Experimental Design...........................................................19 Chapter 2 Experimental Methods 2-1 Reagents, Materials and Apparatus 2-1.1 Chemicals and Reagents...................................................................20 2-1.2 Antibodies........................................................................................22 2-1.3 Liposome Constituents.....................................................................23 2-1.4 Apparatus.........................................................................................23 2-1.5 Cell Lines..........................................................................................24 2-2 Preparation of Liposomes.............................................................................25 2-3 Characterization of Liposomes.....................................................................27 2-4 Cell Culture...................................................................................................29 2-5 Analysis of Activation of Integrin αvβ3.........................................................29 2-6 Cell Viability Assay......................................................................................30 2-7 Quantification of Proteins.............................................................................31 2-8 Liquid-liquid Extraction...............................................................................32 2-9 Western Blot.................................................................................................33 Chapter 3 Results 3-1 Characterizations of Liposomes....................................................................34 3-1.1 Preparation and characterization of liposomes..................................34 3-1.2 Determination of Encapsulation Efficiency......................................35 3-2 Flow Cytometry Analysis of Integrin αvβ3 and Its Active Form Expressions on MCF-7.....................................................................................................36 3-3 Cytotoxicity Assay of Free Dox and Free RSV in MCF-7.............................39 3-4 Cytotoxicity Assay of RMS-Lipo-Dox in MCF-7.........................................41 3-5 Cytotoxicity Assay of RMS-Lipo-Dox in MDA-MB-231............................45 3-6 Quantification of Intranuclear Accumulation of Dox....................................47 3-7 Immunoblotting of RMS-mediated Signaling Pathway................................49 3-8 Cell Morphologies of MCF-7 After Treatments............................................51 Chapter 4 Discussions...........................................................................................55 Chapter 5 Conclusion and Prospect.......................................................................58 Chapter 6 References............................................................................................59 Chapter 7 Appendix..............................................................................................71 | |
dc.language.iso | en | |
dc.title | 設計並探討具高度安全性及標靶功能的奈米藥物於治療乳癌的成效 | zh_TW |
dc.title | A Safety Enhanced, Integrin αvβ3 Targeting Nanodrug for MCF-7 Human Breast Cancer Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳立真,徐士蘭,鄭建中,陳平,楊家銘 | |
dc.subject.keyword | 修飾白藜蘆醇的硬脂酸,微脂體,組合蛋白αvβ3,阿黴素,熱休克蛋白27, | zh_TW |
dc.subject.keyword | Resveratrol-modified stearate,Liposome,Integrin αvβ3,Doxorubicin,Heat shock protein 27, | en |
dc.relation.page | 74 | |
dc.identifier.doi | 10.6342/NTU201602759 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-19 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-R03b22029-1.pdf 目前未授權公開取用 | 2.7 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。